Insider Selling: Monte Rosa Therapeutics (NASDAQ:GLUE) Insider Sells 5,407 Shares

Monte Rosa Therapeutics, Inc. (NASDAQ:GLUE) insider Filip Janku sold 5,407 shares of the company’s stock in a transaction that occurred on Tuesday, June 30th. The stock was sold at an average price of $24.50, for a total transaction of $132,471.50. Following the sale, the insider directly owned 60,612 shares in the company, valued at approximately $1,484,994. The trade was a 8.19% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through the SEC website.

Filip Janku also recently made the following trade(s):

• On Monday, June 29th, Filip Janku sold 6,000 shares of Monte Rosa Therapeutics stock. The stock was sold at an average price of $22.95, for a total transaction of $137,700.00.
• On Tuesday, June 23rd, Filip Janku sold 11,845 shares of Monte Rosa Therapeutics stock. The shares were sold at an average price of $20.22, for a total transaction of $239,505.90.
• On Wednesday, June 24th, Filip Janku sold 30,000 shares of Monte Rosa Therapeutics stock. The shares were sold at an average price of $21.42, for a total transaction of $642,600.00.

Monte Rosa Therapeutics Stock Performance

Shares of NASDAQ:GLUE traded down $0.18 during trading on Wednesday, hitting $24.02. The company’s stock had a trading volume of 1,366,705 shares, compared to its average volume of 1,377,866. Monte Rosa Therapeutics, Inc. has a fifty-two week low of $4.12 and a fifty-two week high of $25.77. The business has a 50 day moving average price of $19.15 and a two-hundred day moving average price of $18.74. The company has a market capitalization of $2.03 billion, a PE ratio of -16.23 and a beta of 1.60.

Monte Rosa Therapeutics (NASDAQ:GLUE) last announced its quarterly earnings data on Thursday, May 7th. The company reported ($0.45) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.39) by ($0.06). The company had revenue of $4.21 million during the quarter, compared to analyst estimates of $10.95 million. Monte Rosa Therapeutics had a negative net margin of 302.69% and a negative return on equity of 40.99%. As a group, equities analysts expect that Monte Rosa Therapeutics, Inc. will post -1.23 earnings per share for the current fiscal year.

Hedge Funds Weigh In On Monte Rosa Therapeutics

A number of institutional investors and hedge funds have recently added to or reduced their stakes in GLUE. Vanguard Group Inc. raised its holdings in Monte Rosa Therapeutics by 8.6% during the fourth quarter. Vanguard Group Inc. now owns 3,246,500 shares of the company’s stock worth $50,905,000 after purchasing an additional 257,547 shares in the last quarter. Strs Ohio acquired a new position in shares of Monte Rosa Therapeutics in the 4th quarter valued at $566,000. Massachusetts Financial Services Co. MA acquired a new position in shares of Monte Rosa Therapeutics in the 4th quarter valued at $778,000. AXQ Capital LP purchased a new position in shares of Monte Rosa Therapeutics in the 4th quarter valued at $215,000. Finally, ProShare Advisors LLC grew its position in shares of Monte Rosa Therapeutics by 11.8% in the 4th quarter. ProShare Advisors LLC now owns 11,374 shares of the company’s stock valued at $178,000 after buying an additional 1,199 shares during the last quarter. 79.96% of the stock is owned by institutional investors and hedge funds.

Analyst Ratings Changes

Several brokerages have recently issued reports on GLUE. JPMorgan Chase & Co. lifted their price objective on Monte Rosa Therapeutics from $30.00 to $31.00 and gave the company an “overweight” rating in a research note on Monday, May 11th. Wells Fargo & Company decreased their price target on shares of Monte Rosa Therapeutics from $30.00 to $29.00 and set an “overweight” rating for the company in a research note on Wednesday, March 18th. Guggenheim boosted their price target on shares of Monte Rosa Therapeutics from $30.00 to $35.00 and gave the stock a “buy” rating in a report on Tuesday. Weiss Ratings raised shares of Monte Rosa Therapeutics from a “sell (d-)” rating to a “sell (d)” rating in a research report on Monday, May 11th. Finally, Wall Street Zen downgraded shares of Monte Rosa Therapeutics from a “hold” rating to a “sell” rating in a research note on Saturday, March 21st. Seven investment analysts have rated the stock with a Buy rating, one has issued a Hold rating and one has assigned a Sell rating to the company. According to data from MarketBeat.com, the company currently has an average rating of “Moderate Buy” and a consensus price target of $33.33.

Monte Rosa Therapeutics Company Profile

Monte Rosa Therapeutics is a biotechnology company focused on accelerating drug discovery through the integration of single-cell genomics and artificial intelligence. Founded in 2020 and headquartered in Cambridge, Massachusetts, the company has built a proprietary platform designed to identify novel therapeutic targets and optimize lead candidates for areas of high unmet medical need. By combining cutting-edge computational methods with comprehensive cellular profiling, Monte Rosa aims to streamline the preclinical development process and uncover insights into disease biology that might otherwise remain hidden.

The company’s main business activities center on using its AI-driven discovery engine to pursue programs in immuno-oncology and neuroscience.